Zedan Magdy M, Ezz El Regal Mohammed, A Osman Engy, E Fouda Ashraf
Department of Pediatrics, Allergy and Clinical Immunology Unit, Mansoura University, Children Hospital, Mansoura, Egypt.
Iran J Allergy Asthma Immunol. 2010 Sep;9(3):163-8.
Asthma is one of the most common chronic diseases of childhood. Inhaled corticosteroids (ICS) are the recommended controller drug for asthma treatment. The aim of our study was to determine concerns and fears of parents of children with asthma towards the use of ICS. One hundred parents of asthmatic children were interviewed using structural questionnaire. Airway inflammation was reported by only 6% of interviewed parents, whereas airway narrowing was addressed by 34%. Interesting data, 71% of parents were concerned with the role of steroids in asthma treatment, but more than half (53%) of them addressed fears from side effects. Apparent gaps were found in knowledge of parents of asthmatic children about ICS as controller asthma medication. So, physician and health providers should explain to asthmatic parents that airway inflammation is the core for asthma management. This may remove fears about ICS and thus improve adherence to treatment.
哮喘是儿童期最常见的慢性疾病之一。吸入性糖皮质激素（ICS）是推荐用于哮喘治疗的控制药物。我们研究的目的是确定哮喘患儿家长对使用ICS的担忧和恐惧。使用结构化问卷对100名哮喘患儿的家长进行了访谈。只有6%的受访家长提到了气道炎症，而34%的家长提到了气道狭窄。有趣的数据是，71%的家长担心类固醇在哮喘治疗中的作用，但其中超过一半（53%）的家长提到了对副作用的恐惧。哮喘患儿家长对ICS作为哮喘控制药物的知识存在明显差距。因此，医生和医疗服务提供者应向哮喘患儿家长解释，气道炎症是哮喘管理的核心。这可能会消除对ICS的恐惧，从而提高治疗依从性。
